Last Update 03 Mar 26

Fair value Decreased 2.48%

EL: Smart Eyewear Expansion Will Shape Future Outlook For Bullish Thesis

Analysts have trimmed their average price target on EssilorLuxottica to about €316.59 from €324.65, reflecting recent target cuts from several banks, as well as updated assumptions around revenue growth, profit margins and the appropriate discount rate.

Analyst Commentary

Recent research shows a mix of optimism and caution around EssilorLuxottica Société anonyme, with several banks trimming price targets while one major house upgraded its stance. The latest moves cluster around revised expectations for growth, profitability and risk.

Bullish Takeaways

Bullish analysts highlight that, even with lower targets, they still see room between current trading levels and their revised price objectives. They view this as supported by the company’s scale and brand portfolio.
Some see the recent upgrade as a signal that execution on core businesses, such as lenses and frames, could support earnings resilience, even if growth assumptions are now more measured.
The decision by at least one major bank to upgrade rather than downgrade suggests that, in their view, the risk or valuation profile has become more attractive after prior share price moves or earlier target resets.
Supportive ratings, including the maintained Outperform stance at €320, indicate that certain analysts still view the current P/E and broader valuation framework as reasonable relative to the company’s earnings potential.

Bearish Takeaways

Bearish analysts have cut price targets by €10 to €24, signalling more conservative assumptions on revenue growth, margin progression or both. This feeds directly into lower valuation models.
Several target reductions in quick succession point to concerns that previous expectations for profitability and cash generation may have been too optimistic, prompting analysts to reset their forecasts.
The move from €340 to €320 by one bank reflects caution around execution risks, with analysts reassessing how quickly the company can deliver on its operational plans and efficiency goals.
Lower targets, even when positive ratings are maintained, show that some analysts are building in a higher discount rate or risk premium. This reduces the upside they are willing to assign to the shares.

What's in the News

Meta and EssilorLuxottica are reported to be debating pricing and promotion for Ray Ban Meta smart glasses as demand increases, with discussions described as constructive despite internal push and pull (Bloomberg).
Meta and EssilorLuxottica are in talks to potentially double smart glasses production capacity by the end of this year, with Meta reportedly suggesting annual capacity of 20m units or more by the end of 2026, and discussions about capability for over 30m units if demand supports it (Bloomberg).
Meta and EssilorLuxottica have been sued over smart glasses patents, following a filing by Solos Technology (Bloomberg).
EssilorLuxottica renewed its licensing agreement with Burberry for the development, production and global distribution of Burberry branded eyewear, extending the deal from the original expiry on December 31, 2025 through December 31, 2035.
EssilorLuxottica announced a collaboration with Fondazione Chips IT aimed at application specific chip development in an open hardware environment for smart eyewear, including plans to release select wearable platform components as open source hardware.

Valuation Changes

Fair Value: trimmed from €324.65 to €316.59, a reduction of about €8, aligning with the lower average price target.
Discount Rate: raised slightly from 7.25% to about 7.39%, indicating a modestly higher assumed risk or required return.
Revenue Growth: adjusted up from roughly 7.60% to about 9.75%, implying higher top line growth assumptions in the model.
Net Profit Margin: moved down from about 10.96% to roughly 9.82%, reflecting more conservative earnings conversion from € revenue.
Future P/E: eased from about 51.0x to roughly 49.7x, pointing to a slightly lower valuation multiple applied to forward earnings.

4 views

Key Takeaways

Ongoing innovation in vision solutions and smart eyewear, along with strategic acquisitions, enhances competitive advantage and supports future market share and profitability.
Global expansion, supply chain diversification, and direct-to-consumer initiatives drive top-line growth, operational resilience, and recurring revenue opportunities.
Heavy investment in innovative eyewear and premium segments exposes EssilorLuxottica to technology, regulatory, economic, and margin risks amid intensifying competition and global cost pressures.

Catalysts

About EssilorLuxottica Société anonyme

Designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific.What are the underlying business or industry changes driving this perspective?

Strong pipeline of innovation in myopia management solutions (Stellest 2.0, DOT technology) and leadership in addressing rising vision disorders among children globally positions EssilorLuxottica to capture outsized growth from increasing myopia incidence, directly supporting future revenue and market share gains.
Expanding global presence, especially in Asia and Latin America, leverages the growing middle class and improved healthcare access in emerging markets, opening new high-growth channels and supporting sustained top-line expansion.
Investments in smart eyewear, AI-enabled vision solutions, and MedTech (Ray-Ban Meta, Oakley Meta, Nuance Audio, acquisition of Optegra Eye Clinics) capitalize on long-term demand for technologically advanced and personalized eye health platforms, catalyzing product mix upgrades and higher ASPs, which will benefit gross margin and future earnings.
Ongoing vertical integration and supply chain diversification (new production facilities in France, Thailand, Laos, Mexico) improve operational efficiency and mitigate tariff/regulatory headwinds, preserving or expanding operating margins and providing resilience to exogenous shocks.
Accelerating direct-to-consumer and subscription-based channels (notably in Europe and North America), plus deeper engagement with healthcare professionals, enable stronger customer acquisition, higher recurring revenues, and long-term margin improvement, supporting net income and cash flow growth.

EssilorLuxottica Société anonyme Earnings and Revenue Growth

EssilorLuxottica Société anonyme Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming EssilorLuxottica Société anonyme's revenue will grow by 6.1% annually over the next 3 years.
Analysts assume that profit margins will increase from 8.7% today to 11.4% in 3 years time.
Analysts expect earnings to reach €3.7 billion (and earnings per share of €7.88) by about September 2028, up from €2.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €4.2 billion in earnings, and the most bearish expecting €3.0 billion.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 41.6x on those 2028 earnings, down from 50.0x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 47.0x.
Analysts expect the number of shares outstanding to grow by 0.97% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.01%, as per the Simply Wall St company report.

EssilorLuxottica Société anonyme Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The rapid shift towards disruptive optical technologies, such as smart eyewear and AI-enabled glasses, carries substantial execution and adoption risks-if EssilorLuxottica is unable to maintain product relevance, successfully commercialize innovations, or keep pace with technology leaders, it could suffer from slower revenue growth and margin dilution, especially as wearables have been acknowledged as margin dilutive despite their sales momentum.
Intensifying global tariff headwinds and persistent inflationary pressures (notably in the U.S. market) could erode gross margins and net income, with recent results already showing 80-90 basis points of margin dilution and management warning that mitigation strategies like price increases and supply chain relocation may only gradually offset these costs.
The company's aggressive investment in MedTech and a growing assortment of premium/luxury segments (e.g., AI glasses, Stellest lenses, hearing aid eyewear) could make it increasingly vulnerable to economic downturns and cyclical spending contractions, thus exposing revenues and profitability to swings in discretionary consumer income and global macro risks.
EssilorLuxottica's reliance on being the market leader in emerging medical and wearable categories heightens its exposure to tightening regulatory scrutiny and slow or fragmented reimbursement/approval processes (e.g., FDA approval for Stellest lenses), potentially delaying new revenue streams and pressuring earnings if regulatory hurdles or commercialization setbacks occur.
The ongoing expansion of integrated, direct-to-consumer channels and major retail rollouts raises the risk of operational complexity and execution missteps, while at the same time global e-commerce and lower-cost competitors are driving greater price transparency and margin compression-pressuring EssilorLuxottica's long-term revenue growth and its ability to sustain premium pricing.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €265.941 for EssilorLuxottica Société anonyme based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €302.0, and the most bearish reporting a price target of just €180.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be €32.6 billion, earnings will come to €3.7 billion, and it would be trading on a PE ratio of 41.6x, assuming you use a discount rate of 7.0%.
Given the current share price of €258.0, the analyst price target of €265.94 is 3.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on EssilorLuxottica Société anonyme?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

EL: Expansion Into New Optical Markets Will Drive Measured MedTech Momentum